It is well known the incidence of pCR vary among breast cancer-intrinsic subtypes and the patients with HR-positive breast cancer show a low pCR rate compared with triple-negative or HER2-positive breast cancer patients [30, 31]. This evidence concerns the gene ERBB2 and breast cancer.